-
1Academic Journal
Authors: Н. И., Олимова
Source: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 3 No. 7 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 72-75 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 3 № 7 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 72-75 ; 2181-3469
Subject Terms: синдром поликистозных яичников, бесплодие, яичники, гиперандрогения, гирсутизм, овуляция
File Description: application/pdf
-
2Academic Journal
Authors: I. A. Mazerkina, I. G. Davydov, O. S. Alyautdina, И. А. Мазеркина, И. Г. Давыдов, О. С. Аляутдина
Contributors: The study reported in this publication was carried out as part of publicly funded research project No. 056-00026-24-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D reporting No. 124022300127-0)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-00 на проведение прикладных научных исследований (номер государственного учета НИР 124022300127-0).
Source: Safety and Risk of Pharmacotherapy; Том 12, № 2 (2024); 214-229 ; Безопасность и риск фармакотерапии; Том 12, № 2 (2024); 214-229 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-2
Subject Terms: женщины, combined oral contraceptives, oestrogens, progestogens, female infertility, hyperandrogenism, hirsutism, metabolic syndrome, safety of combined oral contraceptives, women, комбинированные оральные контрацептивы, эстрогены, прогестагены, женское бесплодие, гиперандрогения, гирсутизм, метаболический синдром, безопасность комбинированных оральных контрацептивов
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/426/1156; https://www.risksafety.ru/jour/article/downloadSuppFile/426/518; Адамян ЛВ, Андреева ЕН, Абсатарова ЮС, Григорян ОР, Дедов ИИ, Мельниченко ГА и др. Клинические рекомендации «Синдром поликистозных яичников». Проблемы эндокринологии. 2022;68(2):112–27. https://doi.org/10.14341/probl12874; Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. https://doi.org/10.1093/ejendo/lvad096; Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — Part 1. Endocr Pract. 2015;21(11):1291–300. https://doi.org/10.4158/EP15748.DSC; Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — Part 2. Endocr Pract. 2015;21(12):1415–26. https://doi.org/10.4158/EP15748.DSCPT2; Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098; Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res. 2020;12:66–71. https://doi.org/10.1016/j.coemr.2020.03.004; Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–55. https://doi.org/10.1093/humrep/dew218; Emanuel RHK, Roberts J, Docherty PD, Lunt H, Campbell RE, Möller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022;13:1017468. https://doi.org/10.3389/fendo.2022.1017468; Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37. https://doi.org/10.1210/jc.2012-3908; Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89(5):1039–48. https://doi.org/10.1016/j.fertnstert.2008.02.091; Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17(1):17–33. https://doi.org/10.1093/humupd/dmq032; Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (São Paulo). 2015;70(11):765–9. https://doi.org/10.6061/clinics/2015(11)09; Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2022;38(1):e3464. https://doi.org/10.1002/dmrr.3464; Jacewicz-Święcka M, Kowalska I. Changes in metabolic profile in the women with a history of PCOS-A long-term follow-up study. J Clin Med. 2020;9(10):3367. https://doi.org/10.3390/jcm9103367; Wang Y, Ni Z, Li K. The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2021;37(12):1072–8. https://doi.org/10.1080/09513590.2021.1942452; Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;62(2):318–25. https://doi.org/10.1007/s12020-018-1692-3; Bellver J, Rodríguez-Tabernero L, Robles A, Muñoz E, Martínez F, Landeras J, et al. Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet. 2018;35(1):25–39. https://doi.org/10.1007/s10815-017-1047-7; Meczekalski B, Pérez-Roncero GR, López-Baena MT, Chedraui P, Pérez-López FR. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36(4):289–93. https://doi.org/10.1080/09513590.2020.1730794; Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106–7. https://doi.org/10.1001/jamaoncol.2018.5188; Сухих ГТ, Прилепская ВН, ред. Национальные медицинские критерии приемлемости методов контрацепции. М.; 2023. EDN: EFKVBW; Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021;12:769187. https://doi.org/10.3389/fendo.2021.769187; Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. https://doi.org/10.1016/j.beem.2012.09.004; Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7–S16. https://doi.org/10.1016/j.maturitas.2003.09.014; Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. Contraception. 2015;91(6):495–502. https://doi.org/10.1016/j.contraception.2015.03.001; Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263–9. https://doi.org/10.1016/s0002-9378(99)70120-1; Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/ or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011;26(10):2698–708. https://doi.org/10.1093/humrep/der224; Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78(1):16–25. https://doi.org/10.1016/j.contraception.2008.02.019; Ferriman D, Gallwey Jd. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7. https://doi.org/10.1210/jcem-21-11-1440; Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497–506. https://doi.org/10.1016/j.jaad.2018.08.062; Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. https://doi.org/10.1038/nrdp.2016.57; Pasquali R, Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol. 2014;170(2):R75–90. https://doi.org/10.1530/EJE-13-0585; Ceruti JM, Leirós GJ, Balañá ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122–33. https://doi.org/10.1016/j.mce.2017.09.009; Spritzer PM, Marchesan LB, Santos BR, Fighera TM. Hirsutism, Normal androgens and diagnosis of PCOS. Diagnostics (Basel). 2022;12(8):1922. https://doi.org/10.3390/diagnostics12081922; Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19(4):210–23. https://doi.org/10.1111/j.1529-8019.2006.00077.x; Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. https://doi.org/10.1210/jc.2013-2350; Borzyszkowska D, Niedzielska M, Kozłowski M, Brodowska A, Przepiera A, Malczyk-Matysiak K, et al. Evaluation of hormonal factors in acne vulgaris and the course of acne vulgaris treatment with contraceptive-based therapies in young adult women. Cells. 2022;11(24):4078. https://doi.org/10.3390/cells11244078; Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199–204. https://doi.org/10.3109/00016340903353284; Feng JG, Guo Y, Ma LA, Xing J, Sun RF, Zhu W. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. J Cosmet Dermatol. 2018;17(3):511–7. https://doi.org/10.1111/jocd.12387; Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 2016;152(4):391–8. https://doi.org/10.1001/jamadermatol.2015.4498; Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071–83. https://doi.org/10.1210/clinem/dgaa839; Amiri M, Kabir A, Nahidi F, Shekofteh M, Ramezani Tehrani F. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018;23(1):64–77. https://doi.org/10.1080/13625187.2018.1435779; Morgante G, Cappelli V, Troìa L, De Leo V. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2020;25(3):176–81. https://doi.org/10.1080/13625187.2020.1736546; De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88(1):113–7. https://doi.org/10.1016/j.fertnstert.2006.11.137; Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258–64. https://doi.org/10.1210/jc.2017-02052; Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053–9. https://doi.org/10.1016/j.fertnstert.2012.06.035; Tang Z, Guan J, Mao JH, Han L, Zhang JJ, Chen R, Jiao Z. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: a model-based meta-analysis. Eur J Pharm Sci. 2023;190:106577. https://doi.org/10.1016/j.ejps.2023.106577; Dorgham N, Sharobim A, Haggag H, El-Kalioby M, Dorgham D. Adding combined oral contraceptives or metformin to laser treatment in polycystic ovarian syndrome hirsute patients. J Drugs Dermatol. 2021;20(3):302–6. https://doi.org/10.36849/JDD.5652; Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: a meta-analysis. Obstet Gynecol Sci. 2016;59(5):367–72. https://doi.org/10.5468/ogs.2016.59.5.367; Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. https://doi.org/10.1186/s40738-016-0029-2; Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608. https://doi.org/10.1097/MD.0000000000012608; Li Z, Wang YH, Wang LL, Hu DT, Teng Y, Zhang TY, et al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: an updated meta-analysis. Scott Med J. 2022;67(3):109–20. https://doi.org/10.1177/00369330221107099; Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–27. https://doi.org/10.1016/s0140-6736(96)90806-5; Mørch LS, Hannaford PC, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2018;378(13):1265–6. https://doi.org/10.1056/NEJMc1800054; Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case–control study and meta-analysis. PLOS Medicine. 2023;20(3):e1004188. https://doi.org/10.1371/journal.pmed.1004188; Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ oral contraception study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9. https://doi.org/10.1016/j.ajog.2017.02.002; Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015;136(1):99–103. https://doi.org/10.1016/j.ygyno.2014.11.012; Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–5. https://doi.org/10.1016/j.steroids.2013.04.004; Indhavivadhana S, Rattanachaiyanont M, Wongwananuruk T, Techatraisak K, Rayasawath N, Dangrat C. Endometrial neoplasia in reproductive-aged Thai women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2018;142(2):170–5. https://doi.org/10.1002/ijgo.12522; Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21(12):2303–8. https://doi.org/10.1007/s10552-010-9658-7; Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110(5):794–809. https://doi.org/10.1016/j.fertnstert.2018.08.021; Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. J Clin Endocrinol Metab. 2011;96(6):1737–46. https://doi.org/10.1210/jc.2010-2600; Li X, Feng Y, Lin JF, Billig H, Shao R. Endometrial progesterone resistance and PCOS. J Biomed Sci. 2014;21(1):2. https://doi.org/10.1186/1423-0127-21-2; Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30. https://doi.org/10.1200/JCO.2016.69.4638; Pérez-Martín AR, Castro-Eguiluz D, Cetina-Pérez L, Velasco-Torres Y, Bahena-González A, Montes-Servín E, et al. Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention. Bosn J Basic Med Sci. 2022;22(4):499–510. https://doi.org/10.17305/bjbms.2021.6963; Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4(4):516–21. https://doi.org/10.1001/jamaoncol.2017.4942; Burchardt NA, Shafrir AL, Kaaks R, Tworoger SS, Fortner RT. Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947– 1964: The Nurses’ Health Study II, a prospective cohort study. Eur J Epidemiol. 2021;36(8):827–39. https://doi.org/10.1007/s10654-020-00705-5; Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–91. https://doi.org/10.1093/humrep/dex044; Довженко ТВ, Ильина НА, Гродницкая ЕА. Проблема психических нарушений при синдроме поликистозных яичников. Социальная и клиническая психиатрия. 2015;25(2):94–100. EDN: UZQCVP; Edwards AC, Lönn SL, Crump C, Mościcki EK, Sundquist J, Kendler KS, Sundquist K. Oral contraceptive use and risk of suicidal behavior among young women. Psychol Med. 2022;52(9):1710–7. https://doi.org/10.1017/S0033291720003475; Jung SJ, Cho SMJ, Kim HC. Association of oral contraceptive use with suicidal behavior among representative Korean population: results from Korea National Health and Nutrition Examination Survey (2007–2016). J Affect Disord. 2019;243:8–15. https://doi.org/10.1016/j.jad.2018.09.004; Yang Q, Lagerberg T, Sjölander A, Bertone-Johnson ER, Fang F, Ye W, et al. Use of hormonal contraceptives and antidepressants and risks of suicidal behavior and accidents among women with premenstrual disorders: a nationwide cohort study. BMC Med. 2022;20(1):482. https://doi.org/10.1186/s12916-022-02671-z; Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101(8):2966–74. https://doi.org/10.1210/jc.2016-1896; Cinar N, Harmanci A, Demir B, Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod. 2012;27(6):1840–5. https://doi.org/10.1093/humrep/des113; Amisi CA. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022;13(3):129–49. https://doi.org/10.4239/wjd.v13.i3.129; Barber TM. Why are women with polycystic ovary syndrome obese? British Medical Bulletin. 2022;143(1):4–15. https://doi.org/10.1093/bmb/ldac007; Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2022;13:892125. https://doi.org/10.3389/fendo.2022.892125; Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: a large Canadian cohort. J Obstet Gynaecol Can. 2019;41(10):1453–60. https://doi.org/10.1016/j.jogc.2018.11.026; Болотова ЕВ, Дудникова АВ, Крутова ВА, Просолупова НС. Частота и структура метаболических нарушений у женщин с ожирением в сочетании с синдромом поликистозных яичников. Ожирение и метаболизм. 2021;18(3):254–62. https://doi.org/10.14341/omet12374; Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455–67. https://doi.org/10.1093/humupd/dmy007; Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937. https://doi.org/10.1016/j.molmet.2020.01.001; Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036–47. https://doi.org/10.1080/01443615.2017.1318840; Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32(5):343–53. https://doi.org/10.3109/09513590.2015.1117069; Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus—a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423–31. https://doi.org/10.1093/humrep/dew329; Forslund M, Landin-Wilhelmsen K, Trimpou P, Schmidt J, Brännström M, Dahlgren E. Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution. Hum Reprod Open. 2020;(1):hoz042. https://doi.org/10.1093/hropen/hoz042; Kumarendran B, O’Reilly MW, Subramanian A, Šumilo D, Toulis K, Gokhale KM, et al. Polycystic ovary syndrome, combined oral contraceptives, and the risk of dysglycemia: a population-based cohort study with a nested pharmacoepidemiological case-control study. Diabetes Care. 2021;44(12):2758–66. https://doi.org/10.2337/dc21-0437; Wu L, Liu Y, Huang X, Lin K, Liu Y, Li Z, et al. Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: a meta-analysis and systematic review of randomized controlled trials. Clin Endocrinol (Oxf). 2023;99(1):3–16. https://doi.org/10.1111/cen.14895; Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;2014(1):CD003987. https://doi.org/10.1002/14651858.CD003987.pub5; Hirschberg AL, Byström B, Carlström K, von Schoultz B. Reduced serum cholecystokinin and increase in body fat during oral contraception. Contraception. 1996;53(2):109–13. https://doi.org/10.1016/0010-7824(95)00265-0; Arusoglu G, Koksal G, Cinar N, Tapan S, Aksoy DY, Yildiz BO. Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive. J Clin Endocrinol Metab. 2013;98(11):4475–82. https://doi.org/10.1210/jc.2013-1526; Naessén S, Carlström K, Byström B, Pierre Y, Hirschberg AL. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007;32(5):548–54. https://doi.org/10.1016/j.psyneuen.2007.03.008; Lindh I, Ellström AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011;26(7):1917–24. https://doi.org/10.1093/humrep/der094; Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87(3):358–62. https://doi.org/10.1016/j.contraception.2012.07.005; Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009;200(3):329.e1–8. https://doi.org/10.1016/j.ajog.2008.12.052; Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50(4):517–27. https://doi.org/10.1046/j.1365-2265.1999.00701.x; Cooney LG, Dokras A. Cardiometabolic risk in polycystic ovary syndrome: current guidelines. Endocrinol Metab Clin North Am. 2021;50(1):83–95. https://doi.org/10.1016/j.ecl.2020.11.001; Беглова АЮ, Елгина СИ. Метаболические и сердечно-сосудистые риски у женщин репродуктивного возраста с синдромом поликистозных яичников. Мать и дитя в Кузбассе. 2018;(4):44–9. EDN: YRNDGH; Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020;18(1):23. https://doi.org/10.1186/s12958-020-00576-1; Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014;102(5):1444–51.e3. https://doi.org/10.1016/j.fertnstert.2014.08.001; de Medeiros SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2017;15(1):93. https://doi.org/10.1186/s12958-017-0313-y; Yildizhan R, Gokce AI, Yildizhan B, Cim N. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015;31(5):396–400. https://doi.org/10.3109/09513590.2015.1006187; Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sá MF, Ferriani RA. The effects of 2 mg chormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception. 2012;86:268–75. https://doi.org/10.1016/j.contraception.2011.12.011; Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95:1073–9.e1-11. https://doi.org/10.1016/j.fertnstert.2010.12.027; Pinola P, Puukka K, Piltonen TT, Puurunen J, Vanky E, Sundstrom-Poromaa I, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107:788–95.e2. https://doi.org/10.1016/j.fertnstert.2016.12.017; Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67. https://doi.org/10.1161/circulationaha.106.628875; Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112–26. https://doi.org/10.1093/humupd/dmr046; Meun C, Franco OH, Dhana K, Jaspers L, Muka T, Louwers Y, et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study. J Clin Endocrinol Metab. 2018;103:1622–30. https://doi.org/10.1210/jc.2017-02421; Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, Michos ED. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertil Steril. 2022;117(5):924–35. https://doi.org/10.1016/j.fertnstert.2022.03.009; Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol. 2012;119(2 Pt 1):263–9. https://doi.org/10.1097/AOG.0b013e31823f7135; Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36(1):12–23. https://doi.org/10.1080/09513590.2019.1650337; Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96(12):3794–803. https://doi.org/10.1210/jc.2011-1677; Bajuk Studen K, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018;7(7):R238–R251. https://doi.org/10.1530/EC-18-0129; Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception. 2016;94(3):280–7. https://doi.org/10.1016/j.contraception.2015.08.002; Gariani K, Hugon-Rodin J, Philippe J, Righini M, Blondon M. Association between polycystic ovary syndrome and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2020;185:102–8. https://doi.org/10.1016/j.thromres.2019.11.019; Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423. https://doi.org/10.1136/bmj.d6423; Карева ЕН. Тромбозы и гестагены. Доктор.Ру. 2019;(7):57–64. https://doi.org/10.31550/1727-2378-2019-162-7-57-64; Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, de Sá MFS, Toloi MRT. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine (Baltimore). 2015;94(4):e385. https://doi.org/10.1097/MD.0000000000000385; Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–20. https://doi.org/10.1503/cmaj.120677; Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003– 2008. Am J Obstet Gynecol. 2012;207(5):377.e1–8. https://doi.org/10.1016/j.ajog.2012.08.007; Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3:9. https://doi.org/10.1186/s40834-018-0064-y; Landersoe SK, Petersen KB, Vassard D, Larsen EC, Nielsen HS, Pinborg A, et al. Concerns on future fertility among users and past-users of combined oral contraceptives: a questionnaire survey. Eur J Contracept Reprod Health Care. 2019;24(5):347–55. https://doi.org/10.1080/13625187.2019.1639659; Yland JJ, Bresnick KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, et al. Pregravid contraceptive use and fecundability: prospective cohort study. BMJ. 2020;371:m3966. https://doi.org/10.1136/bmj.m3966; Siegel DR, Fresia J, Fought A, Sheeder J, Hampanda K, Appiah L. The effect of hormonal contraception use on ovarian reserve markers and the uptake of assisted reproductive technology in individuals seeking an infertility evaluation. Cureus. 2023;15(6):e40927. https://doi.org/10.7759/cureus.40927; Song SY, Yang JB, Song MS, Oh HY, Lee GW, Lee M, et al. Effect of pretreatment with combined oral contraceptives on outcomes of assisted reproductive technology for women with polycystic ovary syndrome: a meta-analysis. Arch Gynecol Obstet. 2019;300(3):737–50. https://doi.org/10.1007/s00404-019-05210-z; https://www.risksafety.ru/jour/article/view/426
-
3Academic Journal
Source: Репродуктивное здоровье. Восточная Европа. :41-49
Subject Terms: menstrual dysfunction, менструальная дисфункция, 3. Good health, hyperandrogenism, 03 medical and health sciences, гирсутизм, 0302 clinical medicine, гиперандрогения, polycystic ovary syndrome, luteinizing hormone, синдром поликистозных яичников, adolescents, подростки, лютеинизирующий гормон, hirsutism
-
4Academic Journal
Source: Рецепт. :416-429
Subject Terms: 03 medical and health sciences, гирсутизм, 0302 clinical medicine, адреногенитальный синдром, преждевременное половое созревание, congenital adrenal hyperplasia, adrenogenital syndrome, 21-hydroxylase deficiency, дефицит 21-гидроксилазы, врожденная дисфункция коры надпочечников, 3. Good health, hirsutism, precocious puberty
-
5Academic Journal
Authors: G.G. Hasanli
Source: Український журнал Перинатологія і педіатрія, Iss 1(85), Pp 17-21 (2021)
Subject Terms: общий инфантилизм, генитальный инфантилизм, гипогонадотропный гипогонадизм, нормогонадотропный гипогонадизм, гипергонадотропный гипогонадизм, гирсутизм, Pediatrics, RJ1-570
File Description: electronic resource
-
6Academic Journal
Authors: I. V. Kuznetsova, K. R. Nabiyeva, T. I. Romanstova, T. S. Kuzmina
Source: Медицинский совет, Vol 0, Iss 9, Pp 42-48 (2015)
Subject Terms: гирсутизм, угревая сыпь, андрогенная алопеция, синдром поликистозных яичников, ожирение, дислипидемия, комбинированные оральные контрацептивы, дроспиренон, метформин, флутамид, hirsutism, acne, androgenic alopecia, polycystic ovary syndrome, obesity, Medicine
File Description: electronic resource
-
7Academic Journal
Authors: Legro, Richard S., Arslanian, Silva A., Ehrmann, David A., Hoeger, Kathleen M., Murad, M. Hassan, Pasquali, Renato, Welt, Corrine K.
Source: Репродуктивна ендокринологія; № 20 (2014); 22-35
Репродуктивная эндокринология; № 20 (2014); 22-35
Reproductive Endocrinology; № 20 (2014); 22-35Subject Terms: синдром поликистозных яичников, овуляторная дисфункция, гирсутизм, акне, бесплодие, клиническое руководство, Общество ендокринологов США, polycystic ovary syndrome, ovulatory dysfunction, hirsutism, acne, infertility, Clinical Guideline, Endocrine Society
File Description: application/pdf
-
8Academic Journal
Authors: I. V. Kuznetsova, P. A. Nabieva, T. I. Romantsova
Source: Медицинский совет, Vol 0, Iss 17, Pp 118-127 (2014)
Subject Terms: pregnancy, hypovitaminosis, vitamin & mineral supplements, андрогензависимая дермопатия, гирсутизм, акне, алопеция, себорея, комбинированные оральные контрацептивы, антиандрогенные лекарственные средства, Medicine
File Description: electronic resource
-
9Academic Journal
Authors: A. G. Solopova, A. D. Makatsariya, A. E. Solopova, O. V. Nikiforova, А. Г. Солопова, А. Д. Макацария, А. Е. Солопова, О. В. Никифорова
Source: Obstetrics, Gynecology and Reproduction; Vol 11, No 2 (2017); 57-68 ; Акушерство, Гинекология и Репродукция; Vol 11, No 2 (2017); 57-68 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2017.11.2
Subject Terms: лечение, гиперандрогения, бесплодие, гирсутизм, инсулинорезистентность, яичники, диагностика
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/413/612; Хайрутдинова М.Р., Эгамбердиева Л.Д. Вопросы ведения пациентов с овариальными образованиями. Практическая медицина. 2015; 4-1: 191-7.; Шестакова И.Г., Рябинкина Т.С. СПКЯ: новый взгляд на проблему [Под ред. В.Е. Радзинского]. Информационный бюллетень. Status Praesens. 2015. 24 с.; Barthelmess E.K., Naz R.K. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014; 6: 104-19.; Гуламмахмудова Д.В. Клиническое течение синдрома поликистоза яичников у женщин репродуктивного возраста. Вестник РГМУ. 2015; 2: 32-3.; Johansson J., Stener-Victorin E. Polycystic Ovary Syndrome: Effect and Mechanisms of Acupuncture for Ovulation Induction. Evid Based Complement Alternat Med. 2013. 2013: 762615. DOI:10.1155/2013/762615.; Ищенко А.И., Агаджанян Э.С., Ищенко А.А., Горбенко О.Ю. Современные подходы в лечении синдрома Штейна-Левенталя. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2015; 2 (4): 20-5.; Mahalingaiah S., Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets. 2015; 19 (11): 1561-1574. DOI:10.1517/14728222.2015.1101067.; Palomba S., Santagni S., Falbo A., La Sala G.B. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015; 7: 745-63. DOI:10.2147/IJWH.S70314.; Мадянов И.В., Мадянова Т.С. Синдром поликистозных яичников у девочек- подростков как фактор риска сердечно-сосудистых заболеваний. Терапевт. 2012; 5: 34-7.; Randeva H.S., Tan B.K., Weickert M.O., Lois K., Nestler J.E., Sattar N. et al. Cardiometabolic Aspects of the Polycystic Ovary Syndrome. EndocrRev. 2012; 33 (5): 812-41. DOI:10.1210/er.2012-1003.; Солопова А.Г., Солопова А.Е., Чащин А.А., Макацария А.Д. Современные взгляды на патогенез и возможности диагностики эпителиального рака яичников. Акушерство, гинекология и репродукция. 2016; 10 (1): 75-83.; Гавраилова Д. Диабет 2-го типа и синдром поликистозных яичников (СПКЯ). Вестник по педагогике и психологии Южной Сибири. 2014; 3: 60-73.; Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36 (5): 487-525. DOI:10.1210/er.2015-1018.; Rojas J., Chavez-Castillo M., Bermidez V. The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus. Int J Reprod Med. 2014; 2014: 797681. DOI:10.1155/2014/797681.; Синдром поликистозных яичников: руководство для врачей [Под ред. И.И. Дедова, Г.А. Мельниченко]. М.: МИА, 2009. 368 с.; Камилова Н.М., Мастиева Э.А. Оценка эффективности лечения синдрома поликистозных яичников по данным эхографического исследования. Научные ведомости. Серия Медицина. Фармация. 2014; 18 (189): 87-92.; Agapova S., Cameo T., Sopher A.B., Oberfield S.E. Diagnosis and Challenges of Polycystic Ovary Syndrome in Adolescence. Semin Reprod Med. 2014; 32 (3): 194-201. DOI:10.1055/s-0034-1371091.; Clark N., Podolski A.J., Brooks E.D., Chizen D.R., Pierson R.A., Lehotay D.C., Lujan М.Е. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. Reprod Sci. 2014; 21 (8): 1034-43. DOI:10.1177/1933719114522525.; Мамедалиева Н.М., Грушевский В.Е., Суюмбаева Г.М., Апселенова М.К. Современные аспекты синдрома поликистозных яичников (обзор литературы). Вестник Казахского Национального медицинского университета. 2015; 2: 23-7.; Anderson A.D., Solorzano C.M., McCartney C.R. Childhood Obesity and Its Impact on the Development of Adolescent PCOS. Semin Reprod Med. 2014; 32 (3): 202-13. DOI:10.1055/s-0034-1371092.; Tehrani F., Simbar M., Tohidi M., Hosseinpanah F., Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014; 12: 89. DOI:10.1186/1477-7827-12-89.; Sanchez N., Jones H. “Less Than A Wife”: A Study of Polycystic Ovary Syndrome Content in Teen and Women’s Digital Magazines. J Med Internet Res. 2016; 18 (6): e89. DOI:10.2196/jmir.5417.; Abbott D.l-I., Bacha F. Ontogeny of Polycystic Ovary Syndrome and Insulin Resistance In Utero and Early Childhood. Fertil Steril. 2013; 100 (1): 2-11. DOI:10.1016/j.fertnstert.2013.05.023.; De Leo V., Musacchio M., Cappelli V., Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14(1): 38. DOI:10.1186/s12958-016-0173-x.; Михайлова С.В., Зыкова Т.А. Витамин D, аутоиммунные заболевания щитовидной железы и нарушения репродуктивной функции у женщин. Сибирский медицинский журнал. 2013; 7: 13-8.; He C., Lin Z., Robb S.W., Ezeamama A.E. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2015; 7 (6): 4555-77. DOI:10.3390/nu7064555.; Reyes-Mufloz E., Ortega-Gonzalez C., Martinez-Cruz N., Arce-Sanchez L., Estrada-Gutierrez G., Moran С., Sanchez-Serrano А.Р., Higareda-Sanchez R., de la Jara-Diaz J.F. Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical-biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. BMJ Open. 2016; 6 (7): e012107. DOI:10.1136/bmjopen-2016-012107.; Духанина Е.С., Хороших Н.В., Бригадирова В.Ю. Особенности клинической картины синдрома поликистозных яичников на современном этапе. Бюллетень медицинских интернет-конференций. 2015; 5 (12): 1459-60.; Дубинская Е.Д., Гаспаров А.С., Федорова Т.А., Лаптева Н.В. Роль генетических факторов, системы детоксикации и оксидативного стресса при эндометриозе и бесплодии (обзор литературы). Вестник РАМН. 2013; 8: 14-9.; Guo R., Zheng Y., Yang J., Zheng N. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015; 16 (1): 5. DOI:10.1186/s12863-015-0165-4.; Rosenfield R.L. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. JPediatr Adolesc Gynecol. 2015; 28 (6): 412-19. DOI:10.1016/j.jpag.2014.07.016.; Писарева Е.В., Разумная А.Е., Борзенкова А.В. Исследования гормонального статуса женщин с различными нарушениями репродуктивной функции. Вестник СамГУ. Естественнонаучная серия. 2013; 9/1 (110): 191-7.; Dokras A. Cardiovascular Disease Risk in Women with PCOS. Steroids. 2013; 78 (8): 773-6.; Зенкина В.Г. Факторы ангиогенеза при развитии физиологических и патологических процессов женской гонады. Бюллетень сибирской медицины. 2016; 15(4): 111-9.; Dube R. Does endothelial dysfunction correlate with endocrinal abnormalities in patients with polycystic ovary syndrome? Avicenna J Med. 2016; 6 (4): 91-102. DOI:10.4103/2231-0770.191445.; Павлова Т.В., Куликовский В.Ф., Павлова Л.А. Клиническая и экспериментальная морфология. М.: МИА, 2016. 256 с.; Повзун С.А. Общая патологическая анатомия. Спб.: СпецЛит, 2015. 319 с.; Dumesic D.A., Goodarzi М.О., Chazenbalk G.D., Abbottet D.H. Intrauterine Environment and PCOS. Semin Reprod Med. 2014; 32 (3): 159-65. DOI:10.1055/s-0034-1371087.; McAllister J.IVI., Legro R.S., Modi B.P., Strauss J.F. Functional Genomics of PCOS: From GWAS to Molecular Mechanisms. Trends Endocrinol Metab. 2015; 26 (3): 118-24. DOI:10.1016/j.tem.2014.12.004.; Legro R.S., Gnatuk C.L., Kunselman A.R., Dunaif A. Changes in glucose tolerance over time in woman with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90 (6): 3236-42.; Миронова М.П. Современная тактика терапии бесплодия, ассоциированного с синдромом поликистозных яичников. Медицинский вестник Башкортостана. 2013; 6: 113-6.; Соболева Е.Л., Потин В.В., Тарасова М.А. Лечение андрогензависимой дермопатии. Журнал акушерства и женских болезней. 2010; 59 (2): 34-6.; Bachanek M., Abdalla N., Cendrowski K., Sawicki W. Value of ultrasonography in the diagnosis of polycystic ovary syndrome - literature review. J Ultrason. 2015; 15 (63): 410-22. DOI:10.15557/JoU.2015.0038.; Kenigsberg Lf, Agarwal C., Sin S., Shifteh K., Isasi C.R., Crespi R., Ivanova J., Coupey S.M., Heptulla R.A., Arens R. Clinical Utility of Magnetic Resonance Imaging (MRI) and Ultrasonography (US) for Diagnosis of Polycystic Ovary Syndrome (PCOS) in Adolescent Girls. Fertil Steril. 2015; 104 (5): 1302-9. е1-4. DOI:10.1016/j.fertnstert.2015.08.002.; Brown M., Park A.S., Shayya R.F., Wolfson T., Su H.I., Chang R.J. Ovarian Imaging by Magnetic Resonance in Adolescent Girls with Polycystic Ovary Syndrome and Age-Matched Controls. J Magn Reson Imaging. 2013; 38 (3): 689-93. DOI:10.1002/jmri.23992.; Bargiota A., Diamanti-Kendarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab. 2012; 3 (1): 27-47.; Falbo A., Rocca M., Russo T., D'Ettore A., Tolino A., Zullo F., Orio F., Palomba S. Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. J Ovarian Res. 2010; 3 (1): 23. DOI:10.1186/1757-2215-3-23.; Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P, Panidis D., Pawelczyk L., Papavassiliou A.G., Duleba A.J. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007; 127 (6): 581-9.; Mitra S., Nayak P.K., Agrawal S. Laparoscopic ovarian drilling: An alternative but not the ultimate in the management of polycystic ovary syndrome. J Nat Sci Biol Med. 2015; 6 (1): 40-8. DOI:10.4103/0976-9668.149076.; Kong W., Niu X., Zeng T., Lu M., Chen L. Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. PLoS One. 2015; 10 (10): e0140565. DOI:10.1371/journal.pone.0140565.; Arentz S., Abbott J.A, Smith C.A., Bensoussan A. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014; 14: 511. DOI:10.1186/1472-6882-14-511.; Rojas J., Chavez M., Olivar L., Morillo J., Mejias J. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. Int J Reprod Med. 2014; 2014: 719050. DOI:10.1155/2014/719050.; Yang Y.M., Choi E.J. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag. 2015; 11: 1345-53. DOI:10.2147/TCRM.S89737.; Эверт Л.С., Галонский В.Г., Теппер Е.А., Волынкина А.И., Тарасова Н.В. Исходы беременности и состояние здоровья детей, рожденных после применения вспомогательных репродуктивных технологий. Сибирский медицинский журнал (Томск). 2013; 28 (1): 65-9.; Максимова Ж.В., Максимов Д.М. Скрининг: современный взгляд на раннюю диагностику и профилактику хронических неинфекционных заболеваний. Архивъ внутренней медицины. 2014; 6 (20): 52-6.; Comim F.V., Hardy K., Franks S. Adiponectin and Its Receptors in the Ovary: Further Evidence for a Link between Obesity and Hyperandrogenism in Polycystic Ovary Syndrome. PLoS One. 2013; 8 (11): e80416. DOI:10.1371/journal.pone.0080416.; Gao T., Wu L., Chang F., Cao G. Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta¬analysis. Endocr J. 2016; 63 (1): 93-100. DOI:10.1507/endocrj.EJ15-0318.; Tessaro I., Modina S.C., Franciosi F., Sivelli G., Terzaghi L., Lodde V., Luciano A.M. Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. J Ovarian Res. 2015; 8 (1): 64. DOI:10.1186/s13048-015-0192-9.; Dumont A., Robin G., Catteau-Jonard C., Dewailly D. Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol. 2015; 13: 137. DOI:10.1186/s12958-015-0134-9.; Singh AX., Singh R. Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocrinol Metab. 2015; 19 (6): 731-43. DOI:10.4103/2230-8210.167548.; https://www.gynecology.su/jour/article/view/413
-
10Academic Journal
Authors: L. V. Erofeeva, Л. В. Ерофеева
Source: Meditsinskiy sovet = Medical Council; № 2 (2017); 38-44 ; Медицинский Совет; № 2 (2017); 38-44 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-2
Subject Terms: ПМС, COC, chlormadinone acetate, non-contraceptive advantages, polycystic ovarian syndrome, disminorrhea, amenorrhea, acne, hyperandrogenia, hirsutism, seborrhea adiposa, dyspareunia, PMS, КОК, хлормадинона ацетат, неконтрацептивные преимущества, СПКЯ, дисменорея, аменорея, акне, гиперандрогения, гирсутизм, жирная себорея, диспареуния
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/1719/1665; http://www.escrh.eu/events/esc-events/2016 (дата обращения 27.05.2016 ).; Skouby SO. Contraceptive use and behavior in the 21st century: A comprehensive study. Eur J Contracept Reprod Health Care, 2004, 9: 57–68.; Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from RoyalCollege of General Practitioners’OralContraception Study. BMJ, 2010, 340: с927. doi:10.1136/bmj.c927.; WHO. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet, 1995, 346: 1575–82.; Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 1995, 346: 1593–6.; Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, 1995, 346: 1589–93.; Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update, 2006, 12: 169–78.; Wiegratz I, Kuhl H. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care, 2006, 11: 153–61.; van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ, 2009, 339: b2921. doi:10.1136/bmj.b2921.; Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ, 2009, 339: b2890. doi:10.1136/bmj.b2890.; Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care, 2010, 36: 117–22.; Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from RoyalCollege of General Practitioners’OralContraception Study. BMJ, 2010, 340: c927. doi:10.1136/bmj.c927.; Rosendaal F, Helmerhorst Vandenbrouke F. Female hormones and thrombosis. J Arterioscler Thromb Vascul Biol, 2002, 22: 201–10.; Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Nelson AL, et al, eds. Contraceptive technology, 19th revised edn. New York, NY: Ardent Media 2007. http://www.contraceptivetechnology.org/; Potter L, Oakley D, de Leon-Wong E, Сañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect, 1996, 28: 154–8.; Rosemberg M, Waugh MS, Burnhill M. Compliance, counseling and satisfaction with oral contraceptives. A prospective evaluation. Fam Plann Perspect, 1998, 30: 89–104.; Прилепская В.Н. Эволюция контрацепции и репродуктивное здоровье (презентация клинической лекции). Гинекология, 2014, 01: 7-11.; Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care, 2008 Mar, 13(1): 17-24.; Z . Jones AE. Managing the pain of primary and secondary dysmenorrhoea. Nurs Times, 2004, 100: 40-3.; Burnett MA, Antao V, Black A, et al. Prevalence of primary dysmenorrhoea in Canada. J Obstet Gynaecol Can, 2005, 27: 765-70.; Harel Z. Dysmenorrhoea in adolescents. Ann N Y Acad Sci, 2008, 1135: 185-95.; Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhea (Cochrane Review). In: The Cochrane Database of Systematic Reviews. Issue 2, 2004.; Якушевская О.В., Ревазова З.В. Микродозированные оральные контрацептивы в терапии Дисменореи. РМЖ. Акушерство и гинекология, 2014, 1: 1-4.; Pushparajah DS, Röhm P, Höschen K et al. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice. Clin Drug Investig, 2011, 31(20): 121–34.; Rabe T, Hartschuh E, Wahlstrom T et al. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles. Contraception, 2010, 82(4): 358–65.; Унанян А.Л., Коссович Ю.М. Лечебные аспекты применения оральных контрацептивов, содержащих хлормадинона ацетат, у женщин с нарушениями репродуктивной функции. Гинекология, 2013, 2: 15-18.; Тихомиров А.Л., Олейник Ч.Г. Белара – вариант современной контрацепции. РМЖ. Акушерство и гинекология, 2006, 1: 9.; Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception, 2003, 67: 305-312.; Дубницкая Л.В. Лечебные аспекты применения эстроген-гестагенных контрацептивов. РМЖ. Акушерство и гинекология, 2004, 13: 743.; Серов В.Н. Гормональная контрацепция. РМЖ. Акушерство и гинекология, 2005, 17: 1107.; Osayande A. S., Mehulic S. Diagnosis and initial management of dysmenorrheal. Am. Fam. Physician., 2014, 89(5): 341–346.; Woosley JA, Lichstein KL. Dysmenorrhea, the menstrual cycle, and sleep. Behav. Med., 2014, 40(1): 14–21.; Bitzer J, Frey B, von Schönau M et al. Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners? Eur J Contracept Reprod Health Care, 2009, 14(4): 258–67.; Calaf i Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care, 2010, 15: 1–3.; Cagnacci A, Ferrari S, Tirelli A et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception, 2009, 79(2): 111–6.; Alhenc-Gelas M, Plu-Bureau G, Guillonneau S et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. Thromb Haemost, 2004, 2(9): 1594–600.; Winkler UH, Röhm P, Höschen K. An open-label, comparative study of the effects of a dosereduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception, 2010, 81(5): 391–400.; Brucker C, Hedon B et al. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception, 2010, 81(6): 501–9.; Conard J, Plu-Bureau G, Bahi N et al. Progestogen-only contraception in women at; high risk of venous thromboembolism. Contraception, 2004, 70(6): 437–41.; Guido M, Romualdi D, Campagna G et al. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. Reprod Sci, 2010, 17(8): 767–75.; Uras R, Orrù M, Pani F et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception, 2010, 82(2): 131–8.; Твердикова М.А., Гависова А.А., Ревазова З.В. Современный подход в регуляции гиперадрогении у женщин. РМЖ. Акушерство и гинекология, 2013, 1: 1-4.; Goulden V, Stables G, Gunliffe W. Prevalence of facial acne in adults. J Fv Acad Derm, 1999, 44: 577–80.; Воробьева Н.Е., Тарасова М.А. Влияние комбинированного контрацептива с хлормадинона ацетатом на дерматологический и психосоциальный статус пациенток с акне. Гинекология, 2016, 01: 74-78.; Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med, 1995, 98(1A): 80S–88S.; Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones, 2004, 3(1): 9–26.; Held BL, Nader S, Rodriguez-Rigau LJ et al. Acne and hyperandrogenism. J Am Acad Dermatol, 1984, 10(2 Pt. 1): 223–6.; Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med, 1995, 98(1A): 89S–94S.; Caruso S, Rugolo S, Agnello C et al. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med, 2009, 6(12): 3376–84.; De LeoV, di Sabatino A, Musacchio MC et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception, 2010, 82(3): 276–80.; Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acneprone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drugs Investig, 2008, 28(11): 703–11.; Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinylestradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception, 2009, 79(1): 15–23.; Anthuber S, Schramm GA, Heskamp ML. Sixmonth evaluation of the benefits of the lowdose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drugs Investig, 2010, 30(4): 211–20.; Gómez M Vázquez, Navarra Amayuelas R, Lamarca M et al. Ethinylestradiol/ Chlormadinone acetate for use in dermatological disorders. Am J Clin Dermatol (Suppl. 1), 2011, 6(12): 13–9.; Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception, 2003, 67(4): 305–12.; Contreras CM, Azamar-Arizmendi G, Saavedra M, Hernández-Lozano M. A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study. Arch Med Res, 2006, 37(7): 907–13.; Bitzer J. Belara – proven benefits in daily practice. Eur J Contracept Reprod Health Care, 2005, 10(Suppl.1): 19–25.; Huber JC, Heskamp ML, Schramm GA. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin Drugs Investig, 2008, 28(12): 783–91.; Куликов И.А, Овсянникова Т.В. Предменструальный синдром: возможности терапии. Гинекология, 2014, 16(2): 60-61.; Plewig G, Cunliffe WJ, Binder N, Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception, 2009, 80(1): 25–33.; Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetatecontaining oral contraceptive – the Contraceptive Switch Study. Contraception, 2007, 76(2): 84–90.; Uras R, Orrù M, Etzi R et al. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. Contraception, 2009, 79(2): 117–21.; Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) – an open-label, prospective, noncontrolled, office-based Phase III study. Contraception, 2008, 77(5): 337–43.; Пеcтрикова Т.Ю., Юрасова Е.А, Никоноркина И.Ю. Оценка лечебных эффектов и влияния на сексуальную активность препарата Белара. Гинекология, 2015, 03: 88-92.
-
11Academic Journal
Authors: N I Volkova, A N Rymashevsky, T A Dimitriadi
Source: RUDN Journal of Medicine, Vol 0, Iss 4, Pp 99-103 (2010)
Subject Terms: гиперандрогения, акне, гирсутизм, Medicine
File Description: electronic resource
-
12Academic Journal
Authors: M. A. Gevorkyan, D. V. Blinov, S. O. Smirnova, М. А. Геворкян, Д. В. Блинов, С. О. Смирнова
Source: Obstetrics, Gynecology and Reproduction; Vol 6, No 1 (2012); 39-49 ; Акушерство, Гинекология и Репродукция; Vol 6, No 1 (2012); 39-49 ; 2500-3194 ; 2313-7347
Subject Terms: дроспиренон, hirsutism, acne, COC, GnRH, FSH, estradiol, drospirenone, гирсутизм, акне, КОК, ГнРГ, ЛГ, ФСГ, эстрадиол
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/312/404; Алесина И.Л. Консультирование женщин как важный инструмент при индивидуальном подборе метода контрацепции. Акушерство и гинекология. 2011; 6: 120-124; Блинов Д.В. Общность ряда нейробиологических процессов при расстройствах деятельности ЦНС. Эпилепсия и Пароксизмальные Состояния. 2011; 2: 28-33; Геворкян М.А., Манухин И.Б., Кузнецова Е.М. Опыт применения дроспиренон содер жащего гормонального контрацептива. РМЖ. 2011; 19(2).; Геворкян М.А., Манухин И.Б., Студеная Л.Б., Смирнова Л.И., Манухина Е.И. Клиника, диагностика и лечение синдрома поликистозных яичников. ЖРОАГ. 2008; 4: 35-48.; Геворкян М.А., Манухин И.Б., Студеная Л.Б., Смирнова Л.И., Манухина Е.И. Синдром поликистозных яичников (патогенез, клиника, диагностика и лечение). Москва. Оржин. 2008; 32 с.; Григорян О.Р., Макарова И.И., Гродницкая Е.Э., Андреева Е.Н. Особенности синдрома поликистозных яичников у женщин с сахарным диабетом 1-го типа (обзор литературы). Проблемы репродукции. 2009; 1: 57-62; Гуриев Т.Д. Синдром поликистозных яичников. Акушерство, гинекология и репродукция. 2010; N2: c.10-15; Демидова Т.Ю. Ожирение и инсулинорезистентность. Трудный Пациент. 2006; 7: 25-28.; Ингибиторы редуктазы в терапии синдрома поликистозных яичников. Акушерство, гинекология и репродукция. 2008; 6: 3.; Ковальский Г.Б., Китаев Э.М., Рыжавский Б.Я. и др. Структурные основы генеративной и эндокринной функции яичников в норме и патологии. Санкт-Петербург. 1996; 176-182.; Крейгхилл М. Детская гинекология//Педиатрия, ред. Греф Д., М., 1997. -С. 457-481.; Лавин Н. Эндокринология. Пер. с англ. В.И. Кандрор. Москва. Практика. 1999.; Манушарова М.А., Черкесова Э.И. Синдром поликистозных яичников: клиника, диагностика, лечение. Лечащий Врач. 2005; 10.; Ошорова С.Д., Андрущишина Т.Б., Морозова Т.Е. Индивидуализированный выбор антигипертензивных лекарственных средств при метаболическом синдроме: влияние на адипокины, маркеры эндотелиальной дисфункции. 2011; 2; Поздняк А.О. Медикаментозная терапия предменструального синдрома. Акушерство и Гинекология. 2011; 8: 117-120.; Тихомиров А.Л., Лубнин Д.М. Синдром поликистозных яичников: факты, теории, гипотезы. Международный эндокринологический журнал. 2007; 5(11).; Уварова Е.В. Возможности применения комбинированных оральных контрацептивов в пролонгированном режиме при лечении СПКЯ. Проблемы репродукции. 2006; 4: 73-78; Шатунова Е.П., Степанова Ю.В. Применение гормональных контрацептивов в программе реабилитации после перенесенного обострения хронического сальпингоофорита. Акушерство и Гинекология. 2011; 2: 106-110.; Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology & Metabolism. 2006; 91(3): 781-785.; Barnes R.B., Rosenfield R.L., Ehrman D.A. J. Clin. Endocrinol. Metab. 1994; 79: 1328-1332.; Carmina E (February 2004). «Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.». Minerva ginecologica 56 (1): 1-6.; Colonna L., Pacifico V., Lello S., Sorge R., Raskovic D., Primavera G. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol. 2011 Oct 19. [Epub ahead of print] DOI: 1111/j.1468-3083.2011.04292.x; Eden J. Polycystic ovary syndrome. A womans guide to identifuing & managing PCOS. Allen & Unwin. 2005.; Hart R., Hickey M., Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology. 2004; 18(5): 671-683.; Hirshfeld-Cytron J., Barnes R.B., Ehrmann D.A., Caruso A., Mortensen M.M., Rosenfield R.L. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009; 94(5): 1587-1594.; Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-36.; Nillni E.A., Sevarino K.A. The biology of prothyrotropin-releasing hormone-derived peptides. Endocrine Reviews. 1999; 20(5): 599-648.; O’Leary R., O’Connor B. Thyrotropin-releasing hormone. Short review. J. Neurochem. 1995; 65: 953-963.; Polycystic Ovary Syndrome (PCOS). US Department of Health and Human Services. 2008; 29 p.; Stein I.L., Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935; 29: 181-191.; https://www.gynecology.su/jour/article/view/312
Availability: https://www.gynecology.su/jour/article/view/312
-
13Academic Journal
Authors: L. V. Damdinova, O. Ya. Leshchenko, Л. В. Дамдинова, О. Я. Лещенко
Source: Acta Biomedica Scientifica; Том 1, № 5 (2016); 181-186 ; 2587-9596 ; 2541-9420
Subject Terms: кишечная микробиота, Stein-Leventhal syndrome, infertility, oligomenorrhea, insulin resistance, hyperandrogenism, hirsutism, polycystic ovaries, intestinal microbiota, синдром Штейна - Левенталя, бесплодие, олигоменорея, инсулинорезистентность, гиперандрогения, гирсутизм, поликистозные яичники
File Description: application/pdf
Relation: https://www.actabiomedica.ru/jour/article/view/305/306; Алиева Э.А., Овсянникова Т.В., Пшеничникова Т.Я. Бесплодие, обусловленное синдромом поликистозных яичников // Акушерство и гинекология. -1991. - № 6. - С. 59-62; Алиева Э.А., Пшеничникова Т.Я., Гаспаров А.С. Патофизиология синдрома поликистозных яичников // Акушерство и гинекология. - 1989. - № 4. - С. 4-5; Назаренко Т.А., Сотникова Е.И., Дуринян Э.Р. Принципы и схемы стимуляции овуляции при бесплодии, обусловленном нарушениями функции гипоталамо-гипофизарной системы // Акушерство и гинекология. - 1996. - № 5. - С. 46-50; Серов В.Н., Прилепская В.Н., Пшеничникова Т.Я. Практическое руководство по гинекологической эндокринологии. - М.: Русфармомед, 1995. - 440 с; Шипхинеева Т.И., Сутурина Л.В., Даржаев З.Ю., Цыренов Т.Б., Ринчиндоржиева М.П. Характеристика причин эндокринного бесплодия у русских и буряток по данным обращаемости // Бюллетень ВСНЦ СО РАМН. - 2010. - № 6. - С. 99-101; Шулунов С.С., Шенин В.А., Колесникова Л.И., Лабыгина А.В., Сутурина Л.В., Большакова С.Е. Роль полиморфных генов в развитии синдрома поликистозных яичников // Сибирский медицинский журнал. - 2011. - № 7 (106). - С. 5-8; Ahima R.S., Flier J.S. (2000). Adipose tissue as an endocrine organ. Trends Endocrinology Metabolism, (11), 327-332.; Arusoglu G., Koksal G., Cinar N., Tapan S., Aksoy D.Y., Yildiz B.O. (2013). Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive. The Journal of Clinical Endocrinology and Metabolism, (11), 82.; Azziz R., Adashi E.Y. (2016). Stein and Leventhal: 80 years on. Obstetrics Gynecology, (2), 247.; Bhattacharya S., Jha A. (2010). Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertility & Sterility, (94), 357.; Cooper H.E., Spellacy W.N., Prem K.A., Cohen W.D. (1968). Hereditary factors in Stein-Levental syndrome. Obstetrics Gynecology, (7), 371-387.; Deeks A., Gibson-Helm M., Teede H. (2010). Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertility & Sterility, (93), 242.; Elting M.W., Korsen T.J., Bezemer P.D., Schoemaker J. (2001). Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Human Reproduction, (16), 556-560.; Fauser B.C., Tarlatzis B.C., Rebar R.W. (2012). Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Spon-sored 3rd PCOS Consensus Workshop Group. Fertility & Sterility (97), 28-38.; Foster G.D., Sanders M.H., Millman R., Zammit G., Borradaile K.E., Newman A.B., Wadden T.A., Kelley D., Wing R.R., Sunyer F.X., Darcey V., Kuna S.T. (2009). Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care, (32), 1017-1019.; Hahn S., Haselhorst U., Quadbeck B., Tan S., Kimmig R., Mann K., Janssen O.E. (2006). Decreased soluble leptin receptor levels in women with polycystic ovary syndrome. Endocrinology (154), 287-294.; Hla K.M., Young T., Finn L., Peppard P.E., Szklo-Coxe M., Stubbs M. (2008). Longitudinal association of sleep-disordered breathing and nondipping of nocturnal blood pressure in the Wisconsin Sleep Cohort Study. Endocrinology, (31), 795-800.; Mаnsson M. (2008). Women with polycystic ovary syndrome are often depressed or anxious-A case control study. Psychoneuroendocrinology, (33), 1132-1138.; Moran L.J., Noakes M., Clifton P.M., Wittert G.A., Le Roux C.W., Ghatei M.A., Bloom S.R., Norman R.J. (2007). Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. The American Journal of Clinical Nutrition, 86 (6), 1603-1610.; Nobels F., Dewailly D. (1992). Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor hypothesis. Fertility & Sterility, (4), 655-666.; Oei M., Kazer R. (1992). Variability of serum gonadotropin and dehydroepiandrosterone sulfate concentrations in women with polycystic ovary syndrome. Iranian Journal of Reproductive Medicine, (12), 974-979.; Pirwany I.R., Fleming R., Sattar N., Greer I.A., Wallace A.M. (2001). Circulating leptin concentrations and ovarian function in polycystic ovary syndrome. Endocrinology, (145), 289-294.; Pusalkar M., Meherji P., Gokral J., Savardekar L., Chinnaraj S., Maitra A. (2010). Obesity and polycystic ovary syndrome: association with androgens, leptin and its genotypes. Gynecology & Endocrinology, (26), 874-882.; Randeva H.S., Таn B.K., Weickert M.O., Lois K., Nestler J.E., Sattar N., Lehnert H. (2012). Cardiometabolic aspects of the polycystic ovary syndrome. Review of Endocrinology, 33 (5), 812-41.; Sattar N., Wannamethee G., Sarwar N., Chernova J., Lawlor D.A., Kelly A., Wallace A.M., Danesh J., Whincup P.H. (2009). Leptin and coronary heart disease: prospective study and systematic review. Journal of the American College of Cardiology, (153), 167-175.; Scott T. Kelley, Skarra D.V., Rivera A.J., Thackray V.G. (2016). The gut microbiome is altered in a letro-zole-induced mouse model of polycystic ovary syndrome, PLoS ONE, (1) 5; 11 (1). doi:10.1371/journal. pone.0146509.; Somers V.K., White D.P., Amin R., Abraham W.T., Costa F., Culebras A., Daniels S., Floras J.S., Hunt C.E., Olson L.J., Pickering T.G., Russell R., Woo M., Young T. (2008). Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. Journal of the American College of Cardiology, (52), 686-717.; Stein I.F., Levinthal M.L. (1935). Amenorrhea associated with bilateral polycystic ovaries, Obstetrics Gynecology, (29), 181-191.; Tasali E., Chapotot F., Leproult R., Whitmore H., Ehrmann D.A. (2011). Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism (96), 365-374.; Tasali E., Mokhlesi B., Van Cauter E. (2008). Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest Journal, (133), 496-506; Tremellen K., Pearce K. (2012) Dysbiosis of Gut Microbiota (DOGMA) - a novel theory for the development of Polycystic Ovarian Syndrome. Medical Hypotheses, 79 (1), 104. doi:10.1016/j.mehy.2012.04.016 [Pub Med].; Tsilchorozidou T., Batterham R.L., Conway G.S. (2008). Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). Clinical Endocrinology, 69 (6), 936-942.; Vgontzas A.N., Legro R.S., Bixler E.O., Grayev A., Kales A., Chrousos G.P. (2001). Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. The Journal of Clinical Endocrinology and Metabolism, (86), 517-520.; Vrbi'kova J., Ci'fkova R., Jirkovska A., Lanska V., Platilova H., Zamrazil V., Starka L. (2003). Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Human Reproduction, (18), 980-984.; Yildizhan R., Ilhan G.A., Yildizhan B., Kolusari A., Adali E., Bugdayci G. (2011). Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylargi-nine levels in obese and nonobese young women with polycystic ovary syndrome. Fertility & Sterility, (96), 246-250.; Zhao L., Guo Y., Qi Y., Yang X., Wen S., Liu Y., Tang L. (2016). Association between Polycystic Ovary Syndrome and Gut Microbiota, PLoS ONE, 11 (4), doi:10.1371/ journal.pone.0153196 [Pub Med].; Zhao Y., Qiao J. (2013). Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids, (78), 755-760.; Weickert M.O., Hodges P., Tan B.K., Randeva H.S. (2012). Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. Minerva Endocrinologica, 37 (1), 25-40.; https://www.actabiomedica.ru/jour/article/view/305
-
14Academic Journal
Source: Репродуктивна ендокринологія; № 30 (2016); 19-31
Репродуктивная эндокринология; № 30 (2016); 19-31
Reproductive Endocrinology; № 30 (2016); 19-31Subject Terms: 03 medical and health sciences, hyperandrogenism, hirsutism, acne, polycystic ovary syndrome, androgen, a national consensus, 0302 clinical medicine, гіперандрогенія, гірсутизм, акне, синдром полікістозних яєчників, андрогени, національний консенсус, гиперандрогения, гирсутизм, синдром поликистозных яичников, андрогены, национальный консенсус, 3. Good health
File Description: application/pdf
Access URL: http://reproduct-endo.com/article/view/78797
-
15Academic Journal
Authors: Liashuk, P. M., Pashkovska, N. V., Procenko, O. V., Liashuk, R. P.
Source: Clinical and experimental pathology; Vol. 12 No. 1 (2013) ; Клиническая и экспериментальная патология; Том 12 № 1 (2013) ; Клінічна та експериментальна патологія; Том 12 № 1 (2013) ; 2521-1153 ; 1727-4338
Subject Terms: hypertrihosis, hirsutism, virilism, hyperandrogenia, diagnostics, treatment, гипетрихоз, гирсутизм, вирилизм, гиперандрогения, диагностика, лечение, гіпертрихоз, гірсутизм, вірилізм, гіперандрогенія, діагностика, лікування
File Description: application/pdf
-
16Academic Journal
Authors: Барашева, Ольга, Плотникова, Елена, Шабалов, Николай
Subject Terms: ГИПЕРАНДРОГЕНИЯ, ГИРСУТИЗМ, ВИРИЛИЗАЦИЯ, СИНДРОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ, НЕКЛАССИЧЕСКАЯ ФОРМА ВРОЖДЕННОЙ ГИПЕРПЛАЗИИ КОРЫ НАДПОЧЕЧНИКОВ, 21-ГИДРОКСИЛАЗНАЯ НЕДОСТАТОЧНОСТЬ, ПОДРОСТОК, ТЕСТОСТЕРОН, ИНДЕКС СВОБОДНЫХ АНДРОГЕНОВ, ДЕГИДРОЭПИАНДРОСТЕРОНА СУЛЬФАТ, ДИГИДРОТЕСТОСТЕРОН, АНДРОГЕНОВЫЙ РЕЦЕПТОР
File Description: text/html
-
17Academic Journal
Subject Terms: СИНДРОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ, БЕСПЛОДИЕ, ЯИЧНИКИ, ГИПЕРАНДРОГЕНИЯ, ГИРСУТИЗМ, ОВУЛЯЦИЯ
File Description: text/html
-
18Academic Journal
Subject Terms: ГИПЕРАНДРОГЕНИЯ, АКНЕ, ГИРСУТИЗМ
File Description: text/html
-
19Academic Journal
Authors: Захарова, Н., Дворянский, С.
Subject Terms: СИНДРОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ, МЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯ, КОМБИНИРОВАННЫЕ ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫ С ДРОСПИРЕНОНОМ, ФИНАСТЕРИД, НАРУШЕНИЕ МЕНСТРУАЛЬНОГО ЦИКЛА, ГИРСУТИЗМ, БЕСПЛОДИЕ, РOLYCYSTIC OVARY SYNDROME
File Description: text/html
-
20Academic Journal
Authors: Волкова, Н., Рымашевский, А., Димитриади, Т.
Subject Terms: ГИПЕРАНДРОГЕНИЯ, АКНЕ, ГИРСУТИЗМ
File Description: text/html
